<DOC>
	<DOCNO>NCT01433978</DOCNO>
	<brief_summary>Core study : To compare efficacy avatrombopag ( addition standard ) care eltrombopag ( addition standard care ) treatment adult participant chronic immune thrombocytopenia ( idiopathic thrombocytopenic purpura [ ITP ] ) measure durable platelet response . Open-label Extension Phase : To evaluate safety tolerability long-term therapy avatrombopag participant chronic ITP ( cITP ) .</brief_summary>
	<brief_title>A Phase 3 , Multicenter , Randomized , Double-blind , Active-controlled , Parallel-group Trial With Open-label Extension Phase Evaluate Efficacy Safety Oral E5501 Versus Eltrombopag , Adults With Chronic Immune Thrombocytopenia ( Idiopathic Thrombocytopenic Purpura )</brief_title>
	<detailed_description>The study consist three phase : Prerandomization , Randomization ( Core Study ) Extension Phase . Participants 18 year age , meet eligibility requirement , randomize study . It require splenectomized participant make least 35 % study population single platelet count great 35x10^9/L . Participants centrally stratify randomization splenectomy status , baseline platelet count , use concomitant ITP medication baseline randomize receive either double-blind avatrombopag eltrombopag 1:1 ratio . Participants receive blinded therapy start dose 20 mg avatrombopag daily 50 mg eltrombopag daily . Participants allow dose titrate ( maximum dose 40 mg avatrombopag 75 mg eltrombopag ) ( minimum dose 5 mg avatrombopag 25 mg eltrombopag ) depend response study drug . The goal dose modification maintain platelet count level great equal 50x10^9/L less equal 150x10^9/L , decrease need ITP-directed concomitant medication . The duration treatment Core study Extension Phase approximately 26 104 week , respectively .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Men woman great equal 18 year age . 2 . Participants diagnose cITP ( great equal 12 month duration ) accord American Society Hematology/British Committee Standards Hematology ( ASH/BCSH ) guideline , average 2 platelet count less 30x10^9/L ) . The physical exam suggest disease may cause thrombocytopenia ITP . 3 . Participants previously receive one ITP therapy ( include , limited corticosteroid , immunoglobulin , azathioprine , danazol , cyclophosphamide and/or rituximab ) . 4 . Participants must either initially respond ( platelet count great 50x10^9/L ) previous ITP therapy bone marrow examination consistent ITP within 3 year rule myelodysplastic syndrome ( MDS ) cause thrombocytopenia . 5 . Prothrombin time/International Normalized Ratio ( PT/INR ) activate partial thromboplastin time ( aPTT ) must within 80 % 120 % normal range history hypercoagulable state . 6 . A complete blood count within reference range ( include white blood count [ WBC ] differential indicative disorder ITP ) , follow exception : ) Hemoglobin : participant hemoglobin level 10 g/dL ( 100 g/L ) low limit normal ( LLN ) eligible inclusion , anemia clearly attributable ITP ( excessive blood loss ) ; b ) Absolute neutrophil count ( ANC ) great equal 1500/uL ( 1.5x10^9/L ) ( elevate WBC/ANC due corticosteroid treatment acceptable ) . Core Study 1 . Participants know secondary immune thrombocytopenia ( e.g. , participant know Helicobacter pyloriinduced ITP , infect know human immunodeficiency virus [ HIV ] hepatitis C virus [ HCV ] know systemic lupus erythematosus [ SLE ] ) . 2 . Participants consider unable , unwilling comply study protocol requirement give informed consent , determine investigator . 3 . Participants significant medical condition may impact safety participant interpretation study result ( e.g. , acute hepatitis , active chronic hepatitis ; lymphoproliferative disease ; myeloproliferative disorder , leukemia ) . 4 . History MDS . 5 . History pernicious anemia participant vitamin B12 deficiency pernicious anemia exclude cause . 6 . Any prior history arterial venous thrombosis ( stroke , transient ischemic attack , myocardial infarction , deep vein thrombosis , pulmonary embolism ) , two follow risk factor : estrogencontaining hormone replacement contraceptive therapy , smoking , diabetes , hypercholesterolemia , medication hypertension , cancer , hereditary thrombophilic disorder ( e.g. , Factor V Leiden , antithrombin III deficiency , etc . ) , family history arterial venous thrombosis . 7 . Participants history significant cardiovascular disease ( e.g. , congestive heart failure [ CHF ] New York Heart Association Grade III/IV ) , arrhythmia know increase risk thromboembolic event [ e.g. , atrial fibrillation ] , participant QT interval correct heart rate &gt; 450 msec , angina , unstable angina , coronary artery stent placement , angioplasty , coronary artery bypass graft ) . 8 . Participants history cirrhosis , portal hypertension , chronic active hepatitis . 9 . Participants concurrent malignant disease . 10 . Use immunoglobulin ( IVIg antiD ) within 1 week randomization . 11 . Splenectomy use rituximab within 12 week randomization . 12 . Use romiplostim eltrombopag within 4 week randomization . 13 . Participants currently treat corticosteroid azathioprine receive stable dose least 4 week prior randomization complete therapy 4 week prior randomization . 14 . Participants currently treat MMF , CsA , danazol receive stable dose least 12 week prior randomization complete therapy 4 week prior randomization . 15 . Use cyclophosphamide vinca alkaloid regimens within 4 week randomization . 16 . Participants currently treat PPIs H2 antagonist therapy receive stable dose least 6 week prior randomization complete therapy 2 week prior randomization . 17 . Fasting gastrin17 blood level exceed ULN ( include subject PPIs H2 antagonist ) Screening . 18 . Blood creatinine exceed ULN 20 % OR total albumin LLN 10 % ( revise per Amendment 01 ) . 19 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level exceed 2 time ULN ; total bilirubin exceed 1.5 time ULN . 20 . Participants history cancer treatment cytotoxic chemotherapy and/or radiotherapy . 21 . Participants history ITP treatment cytotoxic chemotherapy still eligible enrollment . 22 . Females pregnant ( positive betahuman chorionic gonadotropin [ BhCG ] test ) breastfeeding . 23 . Participants know allergy E5501 eltrombopag excipients . 24 . Participants history significant aminotransferase elevation receive eltrombopag ( defined ALT and/or AST elevation &gt; 3 x ULN ) . 25 . Participants know nonresponders ( defined platelet count never exceed 50 x 10^9/L ) previous TPO agonist therapy ( include previous E5501 therapy ) bone marrow examination consistent ITP take point failure TPO therapy rule MDS cause thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>